Suppr超能文献

[经动脉化疗治疗的不可切除肝细胞癌三年生存病例评估]

[Assessment of three-year survival cases with unresectable hepatocellular carcinoma treated by arterial chemotherapy].

作者信息

Yamashita K, Hirai K, Aoki Y, Sakai T, Majima Y, Tanikawa K

机构信息

Second Dept. of Medicine, Kurume University School of Medicine.

出版信息

Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2969-73.

PMID:2551237
Abstract

The survival rate was studied in 218 patients with unresectable hepatocellular carcinoma (HCC) in whom arterial chemotherapy was performed by one-shot injection of anticancer agents (one-shot therapy) was studied. Tumor factors and clinical features of 6 out of 218 cases with more than 3-year survival, were also studied. The following results were obtained; (1) One-year survival rate of the cases which were compatible with criteria for one-shot therapy in our department was 35.6%, and the three-year rate was 7.0%. On the other hand, one-year survival rate of the cases not compatible with same was 1.5%. The latter survival rate was worse than that for conservative care. (2) The longest survival time was 6 years and 5 months after one-shot therapy. (3) The tumor progression rate was above 40% in 4 out of 6 cases which survived more than 3 years, and tumor thrombus in the portal vein was noted in 3 cases. Clinical stage was I-II. (4) One-shot therapy was performed repeatedly after initial treatment in these 6 cases. In 3 of the 6 cases, TAE or percutaneous ethanol injection therapy was performed for recurrence or progression of HCC during observation. The results suggest that criteria for one-shot therapy and multidisciplinary treatment during observation are necessary.

摘要

对218例无法切除的肝细胞癌(HCC)患者进行了研究,这些患者接受了一次性注射抗癌药物的动脉化疗(一次性治疗)。还研究了218例生存超过3年的患者中的6例的肿瘤因素和临床特征。获得了以下结果:(1)符合我科一次性治疗标准的病例的一年生存率为35.6%,三年生存率为7.0%。另一方面,不符合该标准的病例的一年生存率为1.5%。后者的生存率比保守治疗更差。(2)一次性治疗后的最长生存时间为6年5个月。(3)在生存超过3年的6例患者中,有4例的肿瘤进展率超过40%,3例发现门静脉肿瘤血栓。临床分期为I-II期。(4)这6例患者在初始治疗后重复进行了一次性治疗。在6例中的3例中,在观察期间对HCC的复发或进展进行了TAE或经皮乙醇注射治疗。结果表明,一次性治疗标准和观察期间的多学科治疗是必要的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验